- Current report filing (8-K)
04 12월 2009 - 10:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
December 4, 2009
ALLOS THERAPEUTICS, INC.
(Exact name of registrant
as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number)
|
|
Identification No.)
|
11080
CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address of principal
executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(303) 426-6262
Not
applicable
(Former name or former
address, if changed since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General Instruction A.2.
below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 8
Other Events
Item
8.01
Other Events.
On December 4, 2009,
the Company issued a press release announcing
the execution of a
collaborative agreement with Idis, a UK-based global company, to manage the
named patient program for FOLOTYN (pralatrexate injection) outside of the
United States. The press release is
attached hereto as Exhibit 99.1 and incorporated herein by reference.
Section 9
Financial Statements and Exhibits
Item
9.01
Financial Statements and
Exhibits.
(d)
Exhibits
99.1
|
|
Press
Release, dated December 4, 2009, entitled Allos Therapeutics Announces an Agreement with Idis for a Named
Patient Program for FOLOTYN (pralatrexate injection).
|
2
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
Dated: December 4,
2009
|
ALLOS THERAPEUTICS, INC.
|
|
|
|
|
|
By:
|
/s/ Marc H. Graboyes
|
|
Marc H. Graboyes
|
|
Its:
|
Senior Vice President,
General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated December 4, 2009, entitled Allos Therapeutics Announces
an Agreement with Idis for a Named Patient Program for FOLOTYN (pralatrexate
injection).
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024